AP assessment. (A-F) Assay in AP only buffer (13-mM MgEGTA in GVB0) on DKO cells (A-B,D-F) or CD46KO cells (C). (A) DKO cells were resuspended in MgEGTA with subsequent addition of healthy control serum with or without the addition of eculizumab, sutimlimab, FDi (ACH-5548), or a combination of sutimlimab and FDi. (B-C) Serum from CM03, patient with known FHAA titer of 57 104 AU in AP buffer on either DKO cells (B) or CD46KO cells (C) with or without the addition of FDi or sutimlimab. (D-G) Isolated AP inhibitor titrations. Pooled normal human serum (NHS) from complement technologies was incubated with increasing concentrations of eculizumab (D), FDi (ACH-5548) (E), FBi (iptacopan) (F), or C3 inhibitor (cp40) (G) in AP buffer on DKO cells. Example traces plotted as mean ± SD for each triplicate. RLU, relative luminescence units.
